|
1
|
Falini B, Tiacci E, Martelli MP, Ascani S
and Pileri SA: Acute myeloid leukemia (AML) and related precursor
neoplasms. WHO Classification of Tumors of Haematopoietic and
Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri
SA, Stein H, et al: 4th edition. IARC; Lyon, France: pp. 109–147.
2008
|
|
2
|
Pui CH, Relling MV and Downing JR: Acute
lymphoblastic leukemia. N Engl J Med. 350:1535–1548. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kantarjian HM, O’Brien S, Smith TL, Cortes
J, Giles FJ, Beran M, et al: Results of treatment with hyper-CVAD,
a dose-intensive regimen, in adult acute lymphocytic leukemia. J
Clin Oncol. 18:547–561. 2000.PubMed/NCBI
|
|
4
|
Annino L, Vegna ML, Camera A, Specchia G,
Visani G, Fioritoni G, et al: Treatment of adult acute
lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL
0288 randomized study. Blood. 99:863–871. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cassileth PA, Harrington DP, Appelbaum FR,
Lazarus HM, Rowe JM, Paietta E, et al: Chemotherapy compared with
autologous or allogeneic bone marrow transplantation in the
management to acute myeloid leukemia in first remission. N Engl J
Med. 339:1649–1656. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dworzak MN, Fröschl G, Printz D, Mann G,
Pötschger U, Mühlegger N, et al; Austrian Berlin-Frankfurt-Münster
Study Group. Prognostic significance and modalities of flow
cytometric minimal residual disease detection in childhood acute
lymphoblastic leukemia. Blood. 99:1952–1958. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mortuza FY, Papaioannou M, Moreira IM,
Coyle LA, Gameiro P, Gandini D, et al: Minimal residual disease
tests provide an independent predictor of clinical outcome in adult
acute lymphoblastic leukemia. J Clin Oncol. 20:1094–1104. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Campana D: Determination of minimal
residual disease in leukemia patients. Br J Haematol. 121:823–838.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
San Miguel JF, Vidriales MB, López-Berges
C, Díaz-Mediavilla J, Gutiérrez N, Cañizo C, et al: Early
immunophenotypical evaluation of minimal residual disease in acute
myeloid leukemia identifies different patient risk groups and may
contribute to postinduction treatment stratification. Blood.
98:1746–1751. 2001.
|
|
10
|
Guerrasio A, Pilatrino C, De Micheli D,
Cilloni D, Serra A, Gottardi E, et al: Assessment of minimal
residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid
leukemias by qualitative and quantitative RT-PCR amplification of
fusion transcripts. Leukemia. 16:1176–1181. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
van Dongen JJ, Seriu T, Panzer-Grümayer
ER, Biondi A, Pongers-Willemse MJ, Corral L, et al: Prognostic
value of minimal residual disease in acute lymphoblastic leukaemia
in childhood. Lancet. 352:1731–1738. 1998.
|
|
12
|
Schmidt HH, Strehl S, Thaler D, Strunk D,
Sill H, Linkesch W, et al: RT-PCR and FISH analysis of acute
myeloid leukemia with t(8;21)(p11;p13) and chimeric MOZ and CBP
transcripts: breakpoint cluster region and clinical implications.
Leukemia. 18:1115–1121. 2004. View Article : Google Scholar
|
|
13
|
Fiedler GM, Leichtle AB, Kase J, Baumann
S, Ceglarek U, Felix K, Conrad T, Witzigmann H, Weimann A, Schütte
C, Hauss J, Büchler M and Thiery J: Serum peptidome profiling
revealed platelet factor 4 as a potential discriminating Peptide
associated with pancreatic cancer. Clin Cancer Res. 15:3812–3819.
2009. View Article : Google Scholar
|
|
14
|
Patz EF Jr, Campa MJ, Gottlin EB,
Kusmartseva I, Guan XR and Herndon JE 2nd: Panel of serum
biomarkers for the diagnosis of lung cancer. J Clin Oncol.
25:5578–5583. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Visintin I, Feng Z, Longton G, Ward DC,
Alvero AB, Lai Y, et al: Diagnostic markers for early detection of
ovarian cancer. Clin Cancer Res. 14:1065–1072. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kornblau SM, Tibes R, Qiu YH, Chen W,
Kantarjian HM, Andreeff M, et al: Functional proteomic profiling of
AML predicts response and survival. Blood. 113:154–164. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cui JW, Li WH, Wang J, Li AL, Li HY, Wang
HX, et al: Proteomics-based identification of human acute leukemia
antigens that induce humoral immune response. Mol Cell Proteomics.
4:1718–1724. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liang T, Wang N, Li W, Li A, Wang J, Cui
J, et al: Identification of complement C3f-desArg and its
derivative for acute leukemia diagnosis and minimal residual
disease assessment. Proteomics. 10:90–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cao Y, Wang N, Ying X, Li A, Wang H, Zhang
X and Li W: BioSunMS: a plug-in-based software for the management
of patients information and the analysis of peptide profiles from
mass spectrometry. BMC Med Inform Decis Mak. 9:132009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ng KL and Mishra SK: De novo SVM
classification of precursor microRNAs from genomic pseudo hairpins
using global and intrinsic folding measures. Bioinformatics.
23:1321–1330. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Licastro F, Pedrini S, Ferri C, Casadei V,
Govoni M, Pession A, et al: Gene polymorphism affecting
alpha1-antichymotrypsin and interleukin-1 plasma levels increases
Alzheimer’s disease risk. Ann Neurol. 48:388–391. 2000.PubMed/NCBI
|
|
22
|
Bird PI: Regulation of pro-apoptotic
leucocyte granule serine proteinases by intracellular serpins.
Immunol Cell Biol. 77:47–57. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kloth JN, Gorter A, Fleuren GJ, Oosting J,
Uljee S, ter Haar N, et al: Elevated expression of SerpinA1 and
SerpinA3 in HLA-positive cervical carcinoma. J Pathol. 215:222–230.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lai ML, Rizzo N, Liguori C, Zucca G and
Faa G: Alpha-1-antichymotrypsin immunoreactivity in papillary
carcinoma of the thyroid gland. Histopathology. 33:332–336. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Estellés A, Gilabert J, Grancha S,
Yamamoto K, Thinnes T, España F, et al: Abnormal expression of type
1 plasminogen activator inhibitor and tissue factor in severe
preeclampsia. Thromb Haemost. 79:500–508. 1998.PubMed/NCBI
|
|
26
|
Wang Y, Jiang H, Dai D, Su M, Martinka M,
Brasher P, et al: Alpha 1 antichymotrypsin is aberrantly expressed
during melanoma progression and predicts poor survival for patients
with metastatic melanoma. Pigment Cell Melanoma Res. 23:575–578.
2010. View Article : Google Scholar : PubMed/NCBI
|
